Improving pMDI technique: impacts on carbon footprint

• Research type

  Research Study

• Full title

  A feasibility study of asthma patients attending a secondary care difficult asthma clinic - can we reduce carbon footprint by use of an innovative hardware & software platform (aflo) that trains correct metered dose inhaler (MDI) technique?

• IRAS ID

  333750

• Contact name

  Martin Kelly

• Contact email

  martin.kelly@westerntrust.hscni.net

• Duration of Study in the UK

  0 years, 8 months, 1 days

• Research summary

  Respiratory Analytics will conduct a feasibility study at the Altnagelvin Hospital site in the WHSCT, to evaluate the role and potential for improved inhalation technique and adherence, improved asthma symptom control and the potential for reducing short acting beta agonist (SABA) usage (and consequently the carbon impact), for patients who use pressurised MDIs.
  The study will recruit n = 10 patients with uncontrolled asthma from the uncontrolled asthma clinic at the WHSCT. The data collected over a 24-week period will be used to determine:
  1. whether the afloTM platform improves inhalation technique
  2. whether using the afloTM platform improves user adherence to prescribed preventer medication
  3. whether usage of the afloTM platform leads to reduced usage of SABA reliever medication
  4. whether usage of the afloTM platform leads better asthma control

• REC name

  London - West London & GTAC Research Ethics Committee

• REC reference

  23/PR/1212

• Date of REC Opinion

  9 Nov 2023

• REC opinion

  Further Information Favourable Opinion